Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Mer­ck KGaA said Mon­day it has inked a “de­fin­i­tive agree­ment” to ac­quire Pfiz­er spin­out Spring­Works Ther­a­peu­tics for an eq­ui­ty val­ue of around $3.9 bil­lion, round­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER